GLP-1 drugs may help those with heart failure to stay out of hospital

Embargoed until: Publicly released: 2025-08-31 17:30

International

Photo by Ali Hajiluyi on Unsplash

The GLP-1 weight loss and diabetes drugs semaglutide and tirzepatide may help reduce the risk of hospitalisation and death by up to 40% in patients with heart failure, according to international research. The study of over 58,000 patients who had heart failure with preserved ejection fraction found that those taking semaglutide or tirzepatide had a 40% lower risk of hospitalisation for heart failure or death from any cause compared with those taking another type of glucose-lowering drug.

Media release

From: JAMA

Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
JAMA

Media advisory: This study is being presented at the European Society of Cardiology Congress 2025.

About The Study: In patients with cardiometabolic heart failure with preserved ejection fraction, semaglutide and tirzepatide showed more than 40% risk reduction for the composite of hospitalization for heart failure or all-cause mortality compared with a placebo proxy. Tirzepatide showed no meaningful benefit over semaglutide.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page Please link to the article in online versions of your report (the URL will go live after the embargo ends).

Journal/
conference: JAMA

Research:Paper

Organisation/s: Brigham and Women’s Hospital, USA

Funder: This study was funded by the National Institutes of Health (R01-HL141505, R01-AR080194) and the German Heart Foundation (S/02/24, SRF-HF/24).

Media Contact/s

Contact details are only visible to registered journalists.